DK0822816T3 - Dermatologisk præparat til behandling af actiniske keratoser - Google Patents

Dermatologisk præparat til behandling af actiniske keratoser

Info

Publication number
DK0822816T3
DK0822816T3 DK96912861T DK96912861T DK0822816T3 DK 0822816 T3 DK0822816 T3 DK 0822816T3 DK 96912861 T DK96912861 T DK 96912861T DK 96912861 T DK96912861 T DK 96912861T DK 0822816 T3 DK0822816 T3 DK 0822816T3
Authority
DK
Denmark
Prior art keywords
treatment
actinic keratoses
dermatological preparation
composition
keratoses
Prior art date
Application number
DK96912861T
Other languages
English (en)
Inventor
Bruce E Katz
Original Assignee
Bruce E Katz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bruce E Katz filed Critical Bruce E Katz
Application granted granted Critical
Publication of DK0822816T3 publication Critical patent/DK0822816T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
DK96912861T 1995-04-12 1996-04-10 Dermatologisk præparat til behandling af actiniske keratoser DK0822816T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/421,674 US5627187A (en) 1995-04-12 1995-04-12 5-FU for treating actinic kerotoses
PCT/US1996/005346 WO1996032112A1 (en) 1995-04-12 1996-04-10 Dermatological preparation and method for treating actinic keratoses

Publications (1)

Publication Number Publication Date
DK0822816T3 true DK0822816T3 (da) 2001-11-12

Family

ID=23671557

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96912861T DK0822816T3 (da) 1995-04-12 1996-04-10 Dermatologisk præparat til behandling af actiniske keratoser

Country Status (12)

Country Link
US (2) US5627187A (da)
EP (1) EP0822816B1 (da)
AT (1) ATE203907T1 (da)
AU (1) AU707853B2 (da)
CA (1) CA2215840A1 (da)
DE (1) DE69614375T2 (da)
DK (1) DK0822816T3 (da)
ES (1) ES2162051T3 (da)
GR (1) GR3037031T3 (da)
IL (1) IL117882A0 (da)
PT (1) PT822816E (da)
WO (1) WO1996032112A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
IL140005A0 (en) * 1998-06-26 2002-02-10 Aventis Pharm Prod Inc Method of treatment for dermatological disorders and compositions therefor
WO2002020663A2 (en) * 2000-09-06 2002-03-14 Ap Pharma, Inc. Degradable polyacetal polymers
US6670335B2 (en) 2001-03-05 2003-12-30 A. P. Pharma, Inc. Fluorouracil-containing formulation
US6590059B2 (en) 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
US20030152630A1 (en) * 2001-05-11 2003-08-14 Ng Steven Y. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
NZ575452A (en) 2002-05-24 2010-03-26 Angiotech Int Ag Compositions and methods for coating medical implants such as vascular grafts, catheters, pacemakers etc
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
PL1617832T3 (pl) 2003-04-29 2009-01-30 Orexigen Therapeutics Inc Kompozycje wpływające na utratę wagi
WO2005007129A2 (en) * 2003-07-17 2005-01-27 Angiotech International Ag Topical formulations with bioactive components
US20050136015A1 (en) * 2003-12-17 2005-06-23 McKie Derrick B. Topical use of halosalicylic acid derivatives
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EP2143421A1 (en) * 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
IN2015DN00042A (da) 2012-06-06 2015-05-22 Orexigen Therapeutics Inc
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) * 1957-08-06 S-eluorourace
US2000213A (en) * 1932-07-18 1935-05-07 Standard Brands Inc Process for the manufacture of hydroxy carboxylic acids
US2265945A (en) * 1938-04-09 1941-12-09 Du Pont Organic acid synthesis
US2382889A (en) * 1941-07-22 1945-08-14 Lock Ritchie Hart Manufacture of lactic acid and salts thereof
US2970084A (en) * 1958-01-21 1961-01-31 Miles Lab Production of citric acid by fermentation
US3114770A (en) * 1959-01-20 1963-12-17 Orandi & Massera Sa Ind & Com Recovery of tartaric acid, as the calcium salt, from wine dregs
US2972566A (en) * 1959-12-07 1961-02-21 Kyowa Hakko Kogyo Kk Process for the production of l-malic acid
US3063910A (en) * 1960-02-03 1962-11-13 Kyowa Hakko Kogyo Kk Method of producing l-malic acid by fermentation
US3274074A (en) * 1963-10-24 1966-09-20 Kerr Mc Gee Oil Ind Inc Preparation of salicyclic acid by microbiological oxidation of naphthalene in the presence of a boron compound
US4363815A (en) * 1975-07-23 1982-12-14 Yu Ruey J Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
US4695590A (en) * 1986-05-05 1987-09-22 California Health Technologies Method for retarding aging
US5326790A (en) * 1986-11-19 1994-07-05 Dermatologic Research Corporation Administration of skin medications by use of dicarboxylic acids and derivatives
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US5167649A (en) * 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
KR0133555B1 (ko) * 1989-01-05 1998-04-23 오오쓰까 아끼히꼬 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
US5122514A (en) * 1990-04-23 1992-06-16 Abbott Laboratories Psoriasis treatment
DE19505328C1 (de) * 1995-02-17 1996-06-20 Boehringer Mannheim Gmbh Verwendung von Fluoruracil zur Behandlung von Nagelpilz
DE19549330A1 (de) * 1995-02-17 1996-08-22 Boehringer Mannheim Gmbh Mittel zur Behandlung von Nagelpilz

Also Published As

Publication number Publication date
IL117882A0 (en) 1996-08-04
ES2162051T3 (es) 2001-12-16
EP0822816B1 (en) 2001-08-08
MX9707850A (es) 1998-08-30
EP0822816A1 (en) 1998-02-11
DE69614375T2 (de) 2002-05-23
EP0822816A4 (en) 1998-12-30
AU5553596A (en) 1996-10-30
AU707853B2 (en) 1999-07-22
GR3037031T3 (en) 2002-01-31
US5817666A (en) 1998-10-06
DE69614375D1 (de) 2001-09-13
US5627187A (en) 1997-05-06
ATE203907T1 (de) 2001-08-15
WO1996032112A1 (en) 1996-10-17
CA2215840A1 (en) 1996-10-17
PT822816E (pt) 2002-01-30

Similar Documents

Publication Publication Date Title
DK0822816T3 (da) Dermatologisk præparat til behandling af actiniske keratoser
DE58909793D1 (de) Neue Benzopyran-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung sowie die Verbindungen enthaltenden Zubereitungen
TR199902802T2 (xx) Kardiyovask�ler hastal�klar ve enflamatuar hastal�klar�n tedavisi i�in probukol monoesterleri.
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
DK0980242T3 (da) Anvendelse af fumarsyrederivater til behandling af autoimmunsygdomme
LV12438A (en) Metode of preventing and delyaing the onset of alzheimer's disease and composition thereof
DK90888A (da) Maaleapparat til vaevsmetabolisme
DE69637050D1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer
DK0827408T3 (da) Fremgangsmåde til administration af IGF-I
HUT77631A (hu) Eljárás a levobupivakain és származékai rezolválására
MX9400630A (es) 6-cloro-5-fluoro-3-(2-tenoil)-2-oxindol-1-carboxamida como un agente analgesico y antiinflamatorio.
NO983864L (no) Morfin- og diamorfinsalter av anioniske, ikke-narkotiske analgetika av den substituerte karboksyltypen
DK0871438T3 (da) Anvendelse af alfa-hydroxysyrer ved fremstillingen af et medikament til behandling af inflammation
PT841939E (pt) Agentes terapeuticos e doencas auto-imunes
FI925944A (fi) Arylalkylestrar av 4,5-dihydroxi-9,10-dihydro-9,10-dioxo-2-antracenkarboxylsyra med terapeutisk effekt
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
EE9900010A (et) T-BAM (CD40L) tehnoloogia terapeutilised rakendused silelihasrakkudega seotud haiguste ravimiseks
WO1991015466A3 (en) Aminopolycarboxylic acid chelating agents
AU3409795A (en) Methods for bone healing and fracture repair
DK0808306T3 (da) Hidtil ukendte pyridin- eller pyridazinderivater, fremgangsmåder til fremstilling deraf og lægemidler indeholdende disse fo
NO308195B1 (no) Anvendelse av benzydamin til fremstilling av et legemiddel ved behandling av patologiske tilstander forÕrsaket av TNF
NO972558L (no) Sett for osteoporose-behandlingssyklus
NO952904L (no) Lysinsalt av 6-klor-5-fluor-3-(2-tenoyl)-2-oxindol-1-karboksamide
RU95119892A (ru) Способ выделения цистеиновых катепсинов из экстрактов тканей
MA25278A1 (fr) Procede de therapie des maladies cardiovasculaires utilisant des derives d'aminotetraline.